Trials / Completed
CompletedNCT00713518
Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
Phase II Open Label Multicenter, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled Study Evaluating PF-04523655 Versus Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization (MONET Study).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- Quark Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.5 mg ranibizumab | |
| DRUG | 3 mg PF-04523655 | |
| DRUG | 1 mg PF-04523655 |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-11-01
- Completion
- 2011-07-01
- First posted
- 2008-07-11
- Last updated
- 2012-10-12
Locations
31 sites across 11 countries: United States, Austria, Denmark, Hong Kong, India, Israel, Philippines, South Korea, Spain, Taiwan, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00713518. Inclusion in this directory is not an endorsement.